3 results
8-K
EX-99.1
IVVD
Invivyd Inc
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
). The FDA requires that such reports, using FDA Form 3500, include the following:
Patient demographics and baseline characteristics (e.g., patient
8-K
EX-99.1
IVVD
Invivyd Inc
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
that such reports, using FDA Form 3500, include the following:
Patient demographics and baseline characteristics (e.g., patient identifier, age or date
8-K
EX-99.3
IVVD
Invivyd Inc
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Patient demographics and baseline characteristics (e.g
- Prev
- 1
- Next